They reported that subgroups of patients with HNSCC, who may achieve increased benefit from afatinib, were identified based on prespecified tumor biomarkers (i.e., HPV‐negative, EGFR amplification, low HER3 expression, and high PTEN expression (Cohen et al., 2017). Here, ERBB3 is linked to neoplasm.